Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 12

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 12
---
5,000,000, after deducting fees and offering expenses (assuming the sale of all securities offered hereby, at the fixed                                                                                                                                                 
 public offering price of $3.20 per Unit and no IPO Warrants are exercised. We intend to use the net proceeds we receive from this Primary                                                                                                                                                 
 Offering as follows: (i) up to 80% from the net proceeds of this Offering or $3.52 million will be used for the development of our product                                                                                                                                                
 candidates and conducting the clinical trials; (ii) up to 20% from the net proceeds of this Offering or $880,000 up to a million to explore                                                                                                                                               
 and develop additional new indications beyond our current pipeline. The actual allocation of net proceeds may vary depending on several                                                                                                                                                   
 factors, including the progress of clinical trials, regulatory developments, and evolving strategic priorities. Until fully deployed,                                                                                                                                                     
 we may invest the net proceeds in short-term interest-bearing instruments or use them for general working capital purposes.                                                                                                                                                               |
| Risk Factors                                                                                                                                                                     |     | See the discussion under the caption “Risk Factors” and other information in this Prospectus for a discussion of factors you should carefully consider before deciding to invest in our Common Stock.                                                                                     |

| (1) | As of February 14, 2025 |

| (2) | The                                                                                                                                             
 number of shares of our Common Stock that will be outstanding after this Offering is based on 60,729,100 shares of our Common Stock outstanding 
 as of February 14, 2025 and excludes:                                                                                                           |

| ● | 4,960,000 shares of Common                                                                                                        
 stock issuable upon the exercise of outstanding stock options as of February 2025, granted pursuant to our Global Share Incentive 
 Plan (2021), as amended (the “2021 Plan”), at a weighted-average exercise price of $0.31 per share and                            |

| ● | 2,240,000 shares of Common                                                                                      
 Stock reserved, in the aggregate, for future issuance under our 2021 Plan, as amended, as of February 14, 2025. |

| ● | 6,372,265 Common Stock issuable upon the exercise of                                                              
 our outstanding warrants with the average exercise price of $1.16 per share, exercisable until December 31, 2026; |

Except as otherwise indicated, all information in this Prospectus:

<div align='center'>4

RISK FACTORS</div>

Investing in our Common Stock involves